期刊文献+

系统免疫炎症指数对非小细胞肺癌患者预后的预测作用 被引量:5

Role of Systemic Immune-inflammatory Index in Prognostic Prediction of Patients with Non-small Cell Lung Cancer
原文传递
导出
摘要 目的探讨系统免疫炎症指数(systemic immune-inflammation index,SII)在非小细胞肺癌(non-small cell lung cancer,NSCLC)预后预测中的临床价值。方法回顾性分析2013-01/2015-12月作者医院诊治的396例行手术治疗NSCLC患者临床资料。通过电子病历系统收集术前资料,记录患者总生存期(overall survival,OS)。多因素Cox回归分析NSCLC患者预后的危险因素。结果396例患者中位随访43个月,死亡312例(78.79%),生存84例(21.21%)。受试者工作特征(receiver operating characteristic,ROC)曲线分析显示,中性粒细胞/淋巴细胞比值(neutrophils to lymphocytes ratio,NLR)预测NSCLS患者5年生存状况的曲线下面积(area under the curve,AUC)为0.723(95%CI:0.647~0.799),最佳临界值为2.58。SII预测NSCLS患者5年生存状况的AUC为0.807(95%CI:0.741~0.843),最佳临界值为635.17。高SII组TNM分期Ⅲ期、有淋巴结转移比例高于低SII组(P<0.05),OS、5年生存率低于低SII组(P<0.05)。多因素Cox回归分析显示,TNM分期Ⅲ期(HR=1.71,95%CI:1.24~2.83,P<0.001)、有淋巴结转移(HR=1.71,95%CI:1.13~2.76,P=0.015)、SII>635.17(HR=2.04,95%CI:1.37~5.25,P=0.009)、NLR>2.58(HR=1.29,95%CI:1.06~2.54,P=0.032)是NSCLC患者预后的独立危险因素。结论SII>635.17是NSCLC患者预后的独立危险因素,可预测其远期生存状况。 Objective To investigate the clinical value of systemic immune-inflammation index(SII)in the prognosis of non-small cell lung cancer(NSCLC).Methods The clinical data of 396 NSCLC patients diagnosed and treated in author′s hospital from January 2013 to December 2015 was retrospectively analyzed.Preoperative data was collected by the electronic medical record system,and the overall survival(OS)of the patients were recorded,and the risk factors for the prognosis of NSCLC patients were analyzed by multivariate Cox regression.Results There were 396 patients with a median follow-up of 43 months,among them,312 cases(78.79%)died and 84 cases(21.21%)survived.receiver operating characteristic(ROC)curve analysis showed that the neutrophils to lymphocytes ratio(NLR)predicted that the 5-year survival status of NSCLS patients with area under the curve(AUC)was 0.723(95%CI:0.647-0.799),and the best cut-off value was 2.58.SII predicted that the 5-year survival status of NSCLS patients with AUC was 0.807(95%CI:0.741-0.843),and the best cut-off value was 635.17.TNM stageⅢ,the proportion of lymph node metastasis in high SII group were higher than those in the low SII group(P<0.05),and the OS and 5-year survival rate were lower than those of the low SII group(P<0.05).Multivariate Cox regression analysis showed that TNM stageⅢ(HR=1.71,95%CI:1.24-2.83,P<0.001),lymph node metastasis(HR=1.71,95%CI:1.13-2.76,P=0.015),SII>635.17(HR=2.04,95%CI:1.37-5.25,P=0.009),NLR>2.58(HR=1.29,95%CI:1.06-2.54,P=0.032)were independent risk factors for prognosis of NSCLC patients.Conclusion SII>635.17 is an independent risk factor for the prognosis of NSCLC patients and it can predict their long-term survival.
作者 孙晓庆 宗明园 傅露 SUN Xiaoqing;ZONG Mingyuan;FU Lu(Department of Oncology,the First Affiliated Hospital of Harbin MedicalUniversity,Harbin Heilongjiang150001,China)
出处 《华南国防医学杂志》 CAS 2021年第12期866-870,共5页 Military Medical Journal of South China
基金 黑龙江省自然科学基金(2018023142)
关键词 系统免疫炎症指数 非小细胞肺癌 总生存期 Systemic immune-inflammation index Non-small cell lung cancer Overall survival
  • 相关文献

参考文献19

二级参考文献97

  • 1吴一龙,蒋国梁,廖美琳,周清华,陆舜,王绿化,张力,无.非小细胞肺癌孤立性转移处理共识[J].循证医学,2007,7(2):109-111. 被引量:21
  • 2Menter DG, Tucker SC, Kopetz S,et al. Platelets and cancer: a casu- al or causal relationship: revisited [ J]. Cancer Metastasis Reviews, 2014, 33(1) :231 -269.
  • 3Jurasz P, Alonso - Escolano D, Radomski MW. Platelet - cancer in- teractions, mechanisms and pharmacology of tumour cell - induced platelet aggregation[ J]. British Journal of Pharmacology, 2004, 143 (7) :819 -826.
  • 4Billroth T. Lectures on surgical pathology and therapeutics: a hand-book for students and practitionersed [ M ]. London: The New Syden- ham Society, 1878.
  • 5Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction [ J]. Proceedings of the National Academy of Sciences of the United States of America, 1968, 61 (1) :46 -52.
  • 6Gasic GJ, Gasic TB, Galanti N, et al. Platelet - tumor - cell interac- tions in mice. The role of platelets in the spread of malignant disease [ J]. International Journal of Cancer, 1973, 11 (3) :704 - 718.
  • 7Buergy D, Wenz F, Groden C, et al. Tumor - platelet interaction in solid tumors [ J ]. International Journal of Cancer, 2012, 130 ( 12 ) : 2747 - 2760.
  • 8Aldemir MN, Turkeli M, Simsek M, et al. Prognostic value of base- line neutrophil - lymphocyte and platelet - lymphocyte ratios in local and advanced gastric cancer patients [ J]. Asian Pacific Journal of Cancer Prevention, 2015, 16(14) :5933 -5937.
  • 9Zhang H, Xia H, Zhang L,et al. Clinical significance of preoperative neutrophil - lymphocyte vs platelet - lymphocyte ratio in primary oper- able patients with non -small cell lung cancer[ J]. American Journal of Surgery, 2015, 210(3):526-535.
  • 10Koh CH, Bhoo - Pathy N, Ng KL,et al. Utility of pre - treatment neutrophil - lymphocyte ratio and platelet - lymphocyte ratio as prog- nostic factors in breast cancer[ J]. British Journal of Cancer, 2015, 113(1) :150 -158.

共引文献939

同被引文献42

引证文献5

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部